Immuron Limited reported unaudited sales results for the first half ended December 31, 2018. For the period, the company's sales of AUD 1.083 million.

The company announced that Health Canada has approved the product licence for Travelan, paving the way to re-launch the product within Canada in April 2019. ANB Canada will manage the distribution and marketing of Travelan within the Retail Pharmacy sector, whilst Passport Health will sell the product through their Canadian Travel Medicine Clinic network. Immuron Canada Ltd. was incorporated under the Canadian Business Corporations Act in April 2018. The associated Natural Product Number for Travelan was officially transferred from former distributor Paladin Labs to Immuron Canada Limited in June 2018. A Distribution and Sales Agreement was executed with ANB Canada Inc. in October 2018.